CLDX Q2 2019 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$715,000-74.1% YoY

Gross Profit

-$9M-1309.9% margin

Operating Income

-$12M-1714.3% margin

Net Income

-$12M-1647.4% margin

EPS (Diluted)

$-0.84

QoQ Revenue Growth

-49.8%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$142M

Total Liabilities

$33M

Stockholders' Equity

$110M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$715,000	$3M	-74.1%
Gross Profit	-$9M	-$19M	+49.9%
Operating Income	-$12M	-$17M	+27.4%
Net Income	-$12M	-$16M	+28.2%

Revenue Segments

Grant

$520,00073%

Service

$195,00027%